– Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral technology that allows a safe local sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases, announces that it closed a €7.5m Series A Financing. The round was led by Boehringer Ingelheim Venture Fund alongside existing investors Bpifrance owned fund Innobio, CapDecisif Management and Inserm Transfert. In conjunction with the closing of the Series A financing, Dr Michel Pairet, Boehringer Ingelheim’s head of non-clinical research and development, has been appointed to the Board of Directors.
The proceeds will be used to further developed Eyevensys’ EyeCET platform and lead product, EYS606 for the treatment of Non-Infectious Uveitis (NIU) through pre-clinical development. EYS606 is the first non-viral product that has the potential to treat NIU patients for up to 6 to 12 months following one injection. The treatment uses the Company’s proprietary electro-transfection injection system (ETIS) to deliver plasmids encoding for the production of anti-TNFα in the ciliary muscle of the eye. TNFα is a cytokine that has been shown to play a pivotal role in mediating intraocular inflammation in NIU.
Francine Behar-Cohen, MD, PhD. Founder and Chief Scientific Officer of Eyevensys, said: “We are pleased that our existing investors have taken the decision to make a further financial commitment to Eyevensys. We are also delighted that Boehringer Ingelheim Venture Fund has become a new strategic investor in the company to support our development program. Their expertise and broader capabilities will be invaluable in helping us achieve our ambitions.”
“Eyevensys’ novel approach, which targets pathologies where few therapies are available and offers potential advantages in terms of effectiveness, administration and tolerability makes it a perfect fit with the Boehringer Ingelheim fund’s criteria for investment,” said Dr Michel Pairet, head of non-clinical research and development at Boehringer Ingelheim. “In the future, medicine will increasingly rely on a combination of technologies, as we see here with the combination of gene therapy with a medical device.”